Sanofi SA / BioMap Holdings Limited

AI-enabled biologics discovery (platform across therapeutic areas)

$400.0B Global biologics market 2023 (all therapeutic areas) · 1010 Deal size (USD MM, upfront + model development + R&D/sales milestones across products)

Disease Overview

AI-enabled biologics discovery sits upstream of therapeutic indication, rather than defining a single disease market. In 2023 the global biologics market exceeded $400B in annual sales and continued to grow faster than small molecules, with monoclonal antibodies, multi-specifics, antibody-drug conjugates and cell/gene therapies all demanding more sophisticated protein engineering than classical humanization pipelines deliver. Pharma R&D productivity pressure, rising trial costs (now exceeding $2B per approved drug per Deloitte 2023), and a 90%-plus late-stage attrition rate in biologics made AI-driven candidate generation and lead optimization a strategic priority across the top-25 sponsor list. BioMap's protein large language model is positioned against DeepMind's AlphaFold, Generate Biomedicines' Chroma, Absci's de novo antibody design platform, and Insilico Medicine's Pharma.AI — each offering shortcut paths to developable sequences with optimized expression, immunogenicity and cross-reactivity profiles. Sanofi's choice to partner rather than build internally reflects both the scarcity of combined wet-lab + foundation-model talent and the speed with which Chinese AI-biologics entrants have closed the gap with US platforms on published benchmarks.

Competitive Landscape

The AI-biologics platform landscape is crowded and fast-moving. Foundation-model peers: AlphaFold 2/3 (DeepMind / Isomorphic Labs) — structure prediction gold standard; ESM / ESMFold (Meta AI) — open-source protein LLM; RoseTTAFold / ProteinMPNN (Baker Lab / Generate Biomedicines) — sequence-to-structure and de novo design. Pharma-aligned platforms: Chroma (Generate Biomedicines, in partnership with Novartis, Amgen); Absci (de novo antibody, partnered with AstraZeneca); Exscientia (AI small molecule plus some biologics, merged with Recursion 2024); Insilico Medicine Pharma.AI (TNIK ISM001-055 in Phase 2 for IPF). Biologics-specific engineering peers: Nabla Bio (generative antibody); Aqemia (physics-ML); OmegaFold, ImmunoMind, LabGenius. Sanofi prior moves: OpenAI partnership (2023) for AI tooling; Aily Labs analytics collaboration; this BioMap pact extends the discovery-stage layer. The deal's $10M upfront against $1B+ milestones reflects how pharma values optionality in AI platforms at a time when no platform has yet delivered an approved molecule.